JANUX THERAPEUTICS INC (JANX)
Health Care · biotechnology · NASDAQ
Janux Therapeutics is a clinical-stage biotech developing tumor-activated T-cell engagers and immunomodulators to treat cancer and autoimmune diseases with reduced toxicity.
What JANUX THERAPEUTICS INC does
Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and autoimmune diseases. It utilizes three proprietary technology platforms—TRACTr, TRACIr, and ARM—designed to create bispecific molecules that precisely direct the immune system to eradicate tumors or manage disease while minimizing toxicity to healthy tissue.
Themes: immuno-oncology, T cell engagers, bispecific antibodies, autoimmune diseases, solid tumor therapeutics, precision medicine
Fundamentals
- Price$18.50 as of 2026-10-08 close
- Market cap$1.1B as of 2026-08-04 (share count; price 2026-10-08)
- 1-year return-23.6% 2025-10-08 close $24.20 → 2026-10-08 close $18.50
- P/En/a negative earnings
- ROE-11.9% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta1.11 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How JANX compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How JANUX THERAPEUTICS INC looks technically
JANUX THERAPEUTICS INC (JANX) is trading 22.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 28 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-09-09, pushing above its recent trading range. It is 47.7% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 22.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +22.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.26 | $17.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.07 | $15.07 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 15.75. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 28 trading days ago — a "golden cross", a bullish long-term signal | 28 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 22.8% above | +22.8% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30) | 60.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($15.75 to $18.90) — its "stochastic" reading is 87 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 87.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $35.34 | $35.34 |
|---|---|---|
| From the 52-week high | it is 47.7% below its 52-week high (its highest price of the past year) | -47.6% |
| Above the 52-week low | it is 52.6% above its 52-week low (its lowest price of the past year) | +52.6% |
| Below the 52-week high | it is 47.7% below its highest point of the past year | 47.6% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-09-09, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 24 trading days ago | 24 sessions |
| All-time high | its highest closing price on record is $71.71 (set on 2024-12-05) | $71.71 |
| Given back of the 52-week move | over the past year its closes ranged ($12.18 to $34.74), and it has recovered roughly a quarter of its fall from last year’s high — 28% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.12 to $26.84. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 28.0% |
| From the all-time high | it is 74.2% below its all-time high | -74.2% |
| Nearest price level | it is trading 10.5% above a support level at $16.56 — a price it turned at twice since 2026-04-20, most recently on 2026-07-20. Since 2024-10-08 it has 7 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -10.5% |
| All-time low | its lowest closing price on record is $5.65 (set on 2023-11-10) | $5.65 |
| Above the all-time low | it is 227.4% above its all-time low | +227.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 30th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8879 between its high and its low — about 4.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8879 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $15.87 and $18.02 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $15.87 – $16.95 – $18.02 |
| Typical daily range (% of price) | its price moves about 4.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 3.9 daily ranges above its 200-day average price (22.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.63× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Gap filled | a 2.5% gap up opened on 2026-08-24 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it took 13 sessions to close | 19 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +11.85% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.7 percentage points (the stock lost 7.7% while the market gained 1.0%) | -8.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.2 percentage points (the stock gained 11.0% while the market gained 3.8%) | +7.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 6.4 percentage points (the stock gained 23.8% while the market gained 17.5%) | +6.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 38.5 percentage points (the stock lost 23.6% while the market gained 15.0%) | -38.5% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.7% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.7% of the share price. | +5.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 23% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $14.98 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +23.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $17.57 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | +5.3% |
Price levels it has turned at before
JANX last closed at $18.50 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.56 | Support | 10.5% below the last close | turned there twice · 2026-04-20 to 2026-07-20 |
| $15.61 | Support | 15.6% below the last close | turned there four times · 2026-01-23 to 2026-09-24 |
| $21.85 | Resistance | 18.1% above the last close | turned there twice · 2025-08-11 to 2025-09-25 |
| $14.85 | Support | 19.7% below the last close | turned there twice · 2026-05-14 to 2026-05-22 |
| $22.44 | Resistance | 21.3% above the last close | turned there five times · 2025-04-09 to 2025-10-07 |
| $25.47 | Resistance | 37.7% above the last close | turned there twice · 2025-09-08 to 2025-10-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $15.75.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $21.49 and $25.04 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $15.75.
This reading has stood for 12 trading days, since 2026-09-23.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.39 mean, 1=Strong Buy…5=Strong Sell) — 17 analysts
- Mean price target$36.24 range $14.00 – $75.00; median $29.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for JANX
- Consensus EPS estimate-$0.4884 next reporting period, as of 2026-10-03
- Estimate change, 30 days$0.00 from -$0.4884, on 2026-08-29, 35-day window
- Readings revised upward29% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of recurring operating losses and no commercial product revenue.","Clinical development risks, including the potential failure of product candidates in clinical trials or voluntary discontinuation of programs.","Heavy reliance on additional financing and collaboration agreements to fund future operations."]
What changed in the latest 10-Q
AI-assisted comparison of JANX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) references audited financial statements 'as of and for the year ended December 31, 2025' and Annual Report filed 'February 26, 2026'
- Newer filing adds that JANX014, a double-masked PSMA-targeted TRACTr, 'entered clinical evaluation in April 2026'
- Newer filing adds that JANX013, a PSMA-targeted TRACIr, 'is planned to enter clinical development in the second half of 2026'
- Newer filing states ARM platform 'is designed to enable controlled T cell activation and expansion followed by contraction'
- Newer filing reports 'In February 2026, we initiated a Phase 1 clinical study of our CD19-ARM program (JANX011)' for evaluation in healthy volunteers
- Newer filing states JANX011 'is being developed for autoimmune diseases'
- Newer filing adds paragraph disclosing decision in April 2026 to 'voluntarily discontinue further clinical development of JANX008' with rationale about 'overall magnitude and consistency of activity'
- Newer filing adds BMS to collaboration agreements: 'amounts received under collaboration agreements with Merck Sharp & Dohme Corp. (Merck) and Bristol-Myers Squibb Company (BMS)'
- Newer filing adds JANX014 to list of clinical candidates: 'All of our product candidates and research programs other than JANX007, JANX011 and JANX014 are in preclinical development'
- Newer filing reports net losses for 'three months ended March 31, 2026 and 2025' as '$24.4 million and $23.5 million'
- Newer filing reports accumulated deficit 'As of March 31, 2026' of '$375.7 million'
- Newer filing references 'timing of any revenue recognition under our collaboration agreements with Merck and BMS' (plural)
- Removed:
- Older filing (2025-11-06) references audited financial statements 'as of and for the year ended December 31, 2024' and Annual Report filed 'February 27, 2025'
- Older filing describes ARM platform aimed to 'create differentiated product candidates' with specific characteristics but lacks newer language about 'controlled T cell activation and expansion followed by contraction'
- Older filing states lead ARM program 'a CD19-ARM, has displayed rapid, deep and durable B-cell depletion' (preclinical data language) rather than stating clinical initiation
- Older filing describes JANX008 as 'second clinical candidate' with Phase 1 trial ongoing and positive early data from February 2024
- Older filing lists products other than JANX007 and JANX008 in preclinical development
- Older filing references only Merck collaboration agreement in funding sources
- Older filing reports net losses for 'nine months ended September 30, 2025 and 2024' as '$81.7 million and $48.8 million'
- Older filing reports accumulated deficit 'As of September 30, 2025' of '$319.4 million'
- Older filing references 'timing of any revenue recognition under our collaboration agreement with Merck' (singular)
- Reworded:
- Newer filing: 'The goal of our TRACTr and TRACIr platforms is to provide cancer patients' vs. Older: 'The goal of both platforms is to provide cancer patients'
- Newer filing: 'while overcoming the liabilities associated with prior generations of TCEs' vs. Older: 'but overcome liabilities associated with prior generations of TCEs'
- Newer filing: 'TCE therapeutics have demonstrated potent anti-tumor activity' vs. Older: 'TCE therapeutics have displayed potent anti-tumor activity'
- Newer filing: 'development in solid tumors has been limited by challenges' vs. Older: 'developing TCEs to treat solid tumors has faced challenges'
- Newer filing: 'development in solid tumors has been limited by challenges associated with prior TCE technologies' vs. Older: 'challenges due to the limitations of prior TCE technologies'
- Newer filing: 'JANX007, is a prostate-specific membrane antigen (PSMA)-targeted TRACTr' vs. Older: 'JANX007, is a prostate-specific membrane antigen or PSMA-TRACTr'
- Newer filing omits December 2024 interim data announcement and May 2025 updated results for JANX007 that appeared in older filing
- Newer filing omits detailed description of JANX008's Phase 1 trial status and February 2024 positive early data announcement from older filing
- Notes:
- The texts are not fully comparable as they report different fiscal periods (Q1 2026 vs. nine months ended Q3 2025), affecting loss figures and accumulated deficit
- Older filing text appears truncated at the end, cutting off mid-sentence; comparison is limited to complete text provided
- JANX008 program status fundamentally changed from active clinical development in older filing to discontinued in newer filing
Risk Factors
- Added:
- Reference to Form 10-K filed on February 26, 2026 (newer filing)
- JANX011 and JANX014 added to list of product candidates beyond preclinical development (newer filing)
- Net loss figures for three months ended March 31, 2026 and 2025: $24.4 million and $23.5 million respectively (newer filing)
- Removed:
- Reference to Form 10-K filed on February 27, 2025 (older filing)
- JANX008 removed from list of product candidates beyond preclinical development (older filing)
- Net loss figures for nine months ended September 30, 2025 and 2024: $81.7 million and $48.8 million respectively (older filing)
- Reworded:
- Product candidates list changed from 'JANX007 and JANX008' to 'JANX007, JANX011 and JANX014' in summary section (filed 2026-05-07 vs 2025-11-06)
- Product candidates list changed from 'JANX007 and JANX008' to 'JANX007, JANX011 and JANX014' in main risk factor heading (filed 2026-05-07 vs 2025-11-06)
- Reporting period changed from nine-month period ending September 30 to three-month period ending March 31 (reflecting different quarterly filing dates)
- Notes:
- The newer filing is for a different quarterly period (Q1 2026) compared to the older filing (Q3 2025), which affects the financial figures disclosed
- The Form 10-K reference dates differ (February 26, 2026 vs February 27, 2025), reflecting annual filings made in different years
- Text appears truncated in both source documents at the same point, limiting full comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 2 sells ($85822) — 2 selling insiders
Most recent open-market transaction: 2026-06-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about JANX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding JANX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 14,082,065
- Reported value $216,300,510
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about JANX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
JANX had 5,891,965 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
JANX had 9.64% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.89 days to cover at the same settlement.
- Reported short interest (shares) 5,891,965
- Short interest (% of shares outstanding) 9.64%
- Prior settlement (shares) 6,063,535
- Reported change -2.83%
- Days to cover (reported) 5.89
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Roche (RHHBY)
- Regeneron Pharmaceuticals (REGN)
- MacroGenics (MGNX)
- Xencor (XNCR)
- Incyte (INCY)
- Legend Biotech (LEGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare JANX vs…
JANUX THERAPEUTICS INC is found in…
Frequently asked questions
What does JANUX THERAPEUTICS INC (JANX) do?
Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and autoimmune diseases. It utilizes three proprietary technology platforms—TRACTr, TRACIr, and ARM—designed to create bispecific molecules that precisely direct the immune system to eradicate tumors or manage disease while minimizing toxicity to healthy tissue.
What sector is JANUX THERAPEUTICS INC (JANX) in?
JANUX THERAPEUTICS INC (JANX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are JANUX THERAPEUTICS INC's (JANX) competitors?
Notable peers of JANUX THERAPEUTICS INC (JANX) include Amgen, Roche, Regeneron Pharmaceuticals, MacroGenics and Xencor. This peer set is informational only — not financial advice.
Is JANUX THERAPEUTICS INC (JANX) overbought or oversold right now?
JANUX THERAPEUTICS INC (JANX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 60, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on JANX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.